Test of three targeted medicines for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests trametinib plus everolimus plus lenvatinib in people with advanced solid tumors that have come back or cannot be treated anymore. It aims to control tumor growth and symptoms when standard options have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has come back or is not responding to treatment
- You are between 18 and 85 years old
- Your doctor expects you can live more than 3 months
- Your tumor is not benign (not non-cancer)
- You do not have serious other conditions that would make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This study tests a new treatment (BGB-B2033) for advanced liver cancer that has returned or not responded to previous immune therapy. It compares this new drug to the standard options sorafenib or lenvatinib, which are targeted pills. The goal is to see if BGB-B2033 can help shrink or slow the cancer better than the current treatments.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial tests a new combination of two study drugs (GH55 and GH21) for people with advanced solid tumors that have certain genetic changes. The goal is to see if the combo is safe and can help shrink tumors or slow their growth.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.